Keloid Treatment Study

Researchers at BIDMC are partnering with individuals who have keloids (thick raised scars) to evaluate whether dupilumab can help. Join our compensated study today!

Fast Facts

18-65 years old

one keloid 2+ cm or two keloids 0.4+ cm

no history of HIV, hep b, hep c, or TB

Compensation Provided

Conducted in Boston, MA

Study Background

Keloids are thick, raised scars that form after a wound has healed and can be much larger than the original injury. The purpose of this study is to assess the effectiveness and safety of a medication called dupilumab (Dupixent) in the treatment of keloids.

Your participation in this study may help researchers improve treatment approaches for keloid scars. Further research today and join our compensated study!

Additional Information

The purpose of this research study is to evaluate the efficacy and safety of dupilumab (Dupixent) for keloids.

To learn more about keloids, please reference this website: https://www.aad.org/public/diseases/a-z/keloids-symptoms

You may qualify for this study if you meet the following criteria.

Key Criteria:

  • 18-65 years old
  • One keloid at least 2 cm long, OR two or more keloids that are at least 0.4 wide x 0.4 cm long
  • No history of HIV, hepatitis B, hepatitis C, or tuberculosis
  • Not pregnant, breastfeeding, or planning to become pregnant during the study
  • Not taking other immunosuppressants
  • No acute asthma, acute bronchospasm, or status asthmaticus
  • Have not participated in another study in the last month
  • No treatment for your keloid(s) in the past month
  • No history of cancer
  • No history of organ transplant

The study medication, dupilumab, is taken as an injection under the skin. Study visits will occur about every 4 weeks over the course of 6 months. There may also be up to 2 biopsy visits.

Compensation is provided up to $675 for your time.

There is no cost for you to participate in the study.